Emergent BioSolutions Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Emergent BioSolutions Inc. – Product Pipeline Review – 2016’, provides an overview of the Emergent BioSolutions Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Emergent BioSolutions Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Emergent BioSolutions Inc.

The report provides overview of Emergent BioSolutions Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Emergent BioSolutions Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Emergent BioSolutions Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Emergent BioSolutions Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Emergent BioSolutions Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Emergent BioSolutions Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Emergent BioSolutions Inc. Snapshot 6

Emergent BioSolutions Inc. Overview 6

Key Information 6

Key Facts 6

Emergent BioSolutions Inc. - Research and Development Overview 7

Key Therapeutic Areas 7

Emergent BioSolutions Inc. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Emergent BioSolutions Inc. - Pipeline Products Glance 14

Emergent BioSolutions Inc. - Late Stage Pipeline Products 14

Filing rejected/Withdrawn Products/Combination Treatment Modalities 14

Emergent BioSolutions Inc. - Clinical Stage Pipeline Products 15

Phase II Products/Combination Treatment Modalities 15

Phase I Products/Combination Treatment Modalities 16

Emergent BioSolutions Inc. - Early Stage Pipeline Products 17

Preclinical Products/Combination Treatment Modalities 17

Discovery Products/Combination Treatment Modalities 18

Emergent BioSolutions Inc. - Drug Profiles 19

coagulation factor IX (recombinant) 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

AV-7909 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

otlertuzumab 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

PreviThrax 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

ES-414 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

5-E3 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

antihemophilic factor (recombinant) 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

ES-210 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

ES-301 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

ES-306 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

EV-035 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

GC-072 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

MVA-RSV 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

MVAH-5HA 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Recombinant Protein to Inhibit CD19 and CD3 for B-Cell Lymphoma 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

MonoClonal Antibody for Ebola and Marburg Infections 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Recombinant Protein to Target HER-2 and CD3 for Cancer 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Recombinant Protein to Target RON and CD3 for Cancer 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Vaccines for Undisclosed Indication 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Emergent BioSolutions Inc. - Pipeline Analysis 42

Emergent BioSolutions Inc. - Pipeline Products by Target 42

Emergent BioSolutions Inc. - Pipeline Products by Route of Administration 44

Emergent BioSolutions Inc. - Pipeline Products by Molecule Type 45

Emergent BioSolutions Inc. - Pipeline Products by Mechanism of Action 46

Emergent BioSolutions Inc. - Recent Pipeline Updates 48

Emergent BioSolutions Inc. - Dormant Projects 57

Emergent BioSolutions Inc. - Dormant Projects 57

Emergent BioSolutions Inc. - Discontinued Pipeline Products 58

Discontinued Pipeline Product Profiles 58

Anthrivig 58

Immune Globulin 58

Leucotropin 58

PEP-35 58

TST-10088 58

Emergent BioSolutions Inc. - Company Statement 59

Emergent BioSolutions Inc. - Locations And Subsidiaries 64

Head Office 64

Other Locations & Subsidiaries 64

Appendix 67

Methodology 67

Coverage 67

Secondary Research 67

Primary Research 67

Expert Panel Validation 67

Contact Us 67

Disclaimer 68

List of Tables

List of Tables

Emergent BioSolutions Inc., Key Information 6

Emergent BioSolutions Inc., Key Facts 6

Emergent BioSolutions Inc. – Pipeline by Indication, 2016 8

Emergent BioSolutions Inc. – Pipeline by Stage of Development, 2016 10

Emergent BioSolutions Inc. – Monotherapy Products in Pipeline, 2016 11

Emergent BioSolutions Inc. – Partnered Products in Pipeline, 2016 12

Emergent BioSolutions Inc. – Partnered Products/ Combination Treatment Modalities, 2016 13

Emergent BioSolutions Inc. – Filing rejected/Withdrawn, 2016 14

Emergent BioSolutions Inc. – Phase II, 2016 15

Emergent BioSolutions Inc. – Phase I, 2016 16

Emergent BioSolutions Inc. – Preclinical, 2016 17

Emergent BioSolutions Inc. – Discovery, 2016 18

Emergent BioSolutions Inc. – Pipeline by Target, 2016 42

Emergent BioSolutions Inc. – Pipeline by Route of Administration, 2016 44

Emergent BioSolutions Inc. – Pipeline by Molecule Type, 2016 45

Emergent BioSolutions Inc. – Pipeline Products by Mechanism of Action, 2016 46

Emergent BioSolutions Inc. – Recent Pipeline Updates, 2016 48

Emergent BioSolutions Inc. – Dormant Developmental Projects,2016 57

Emergent BioSolutions Inc. – Discontinued Pipeline Products, 2016 58

Emergent BioSolutions Inc., Other Locations 64

Emergent BioSolutions Inc., Subsidiaries 64

List of Figures

List of Figures

Emergent BioSolutions Inc. – Pipeline by Top 10 Indication, 2016 8

Emergent BioSolutions Inc. – Pipeline by Stage of Development, 2016 10

Emergent BioSolutions Inc. – Monotherapy Products in Pipeline, 2016 11

Emergent BioSolutions Inc. – Pipeline by Top 10 Target, 2016 42

Emergent BioSolutions Inc. – Pipeline by Route of Administration, 2016 44

Emergent BioSolutions Inc. – Pipeline by Molecule Type, 2016 45

Emergent BioSolutions Inc. – Pipeline Products by Top 10 Mechanism of Action, 2016 46

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared